New Delhi: The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announced that Sputnik V has demonstrated 97.2% efficacy against coronavirus in Belarus.
Belarus was the first foreign country to register Sputnik V and use it to vaccinate its population. The effectiveness of Sputnik V was measured based on data from more than 860,000 people who were vaccinated between January and July 2021.
Read also: Fridge-free COVID-19 vaccine for AI detecting virus – What’s latest on coronavirus research
Health ministry data also confirmed the high safety of the Sputnik V vaccine, with no deaths or adverse effects recorded as a result of the vaccine.
According to the RDIF, the efficacy of Sputnik V is 97.6%, based on an analysis of data on coronavirus infection rates in Russia among those vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021.
It said the vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
“Sputnik V pioneered the use of heterogeneous boosting (two different vectors for two shots during immunization between Covid vaccines). This approach provides a longer duration than vaccines using the same delivery mechanism for both shots. provides immunity with”, the RDIF statement read.
It also said that the safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies that were conducted over two decades.
.